𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A cost-effectiveness analysis of the adjuvant treatment of advanced epithelial ovarian carcinoma

✍ Scribed by Schroeder, E.; Burbano-Levy, X.; Wrenn, D.; De La Garza, J.; Garcia-Soto, A.; Schuman, S.; Simpkins, F.; Pearson, J.; Lucci, J.; Diaz, J.

Book ID
122462247
Publisher
Elsevier Science
Year
2013
Tongue
English
Weight
104 KB
Volume
130
Category
Article
ISSN
0090-8258

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Pharmacoeconomic profile of paclitaxel a
Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma : A lifetime cost-effectiveness analysis
✍ Andrea Messori; Michele Cecchi; Paola Becagli; Sabrina Trippoli πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 61 KB πŸ‘ 2 views

medullary recurrence in certain ethnic groups will be the field have read the article. I agree that there is no proof that all-trans retinoic acid (ATRA) therapy confirmed by further observation and analysis of recurrence in the large cooperative group studying APL. predisposes patients to the deve

Adjuvant 32P in the treatment of ovarian
Adjuvant 32P in the treatment of ovarian carcinoma
✍ Kellie S. Condra; William M. Mendenhall; Linda S. Morgan; Robert B. Marcus Jr. πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 71 KB πŸ‘ 2 views

The purpose of this study was to evaluate the efficacy of adjuvant 32 P for patients with high-risk, early-stage ovarian carcinoma. Twenty-five patients underwent apparent complete resection followed by 32 P (15 mCi) at the University of Florida between 1976 and 1993. Minimum and median follow-up ti